Table 10.

Scenario analyses – deterministic results

	Optimal threshold LDL-C (mmol/L)	Mean QALYs	% on ezetimibe	% on inclisiran
Base-case	2.2	6.046	31.2%	13.2%
£15,000 per QALY	2.4	6.021	22.4%	7.8%
£30,000 per QALY	1.7	6.136	61.3%	32.9%
CVD mortality RR	2.7	5.986	9.8%	3.7%
Only PCSK9i	3.2	5.969	4.2%	1.5%
PCSK9i at > 3.5 mmol/L	2.2	6.047	31.2%	13.2%
Atorvastatin cholesterol distribution	2.2	7.753	20.7%	8.9%
Exclude unstable angina	2.2	6.059	31.2%	13.2%
Exclude TIA	2.2	6.046	31.2%	13.2%
Previous statin model utilities	2.2	5.800	31.2%	13.2%
Inclisiran TA Utilities	2.0	6.338	42.3%	18.8%
Ezetimibe 80% adherence	2.4	6.021	17.9%	9.8%
Ezetimibe 50% adherence	2.7	5.993	4.9%	5.9%
Ezetimibe 0% adherence	3.1	5.985	0%	5.9%
Injectables 80% adherence	2.0	6.063	42.3%	15%
Injectables 50% adherence	1.9	6.053	50.6%	11.8%
Injectables 0% adherence	0.8	6.042	99.6%	0%
Different CVD event costs	2.2	6.202	31.0%	12.9%
Volume discounted inclisiran price	1.9	6.095	50.6%	23.7%
Higher inclisiran escalation cost	2.2	6.046	31.2%	13.2%
Pharmacist fee with ezetimibe	2.2	6.046	31.2%	13.2%
Three-cycles LDL-C change adjusted for gender and baseline LDL-C	2.1	6.053	32.9%	14.0%
Statin intolerance	2.2	6.044	37.5%	15.0%

Note: costs are not reported in the table due to the confidentiality of the price of inclisiran and the PCSK9 inhibitors